• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Neuropathy - Pipeline Review, H2 2012 Product Image

Neuropathy - Pipeline Review, H2 2012

  • Published: October 2012
  • 49 pages
  • Global Markets Direct

Neuropathy – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Neuropathy - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Neuropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuropathy. Neuropathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Neuropathy.
- A review of the Neuropathy products under development by companies and universities/research institutes based on information derived from company READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Neuropathy Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Neuropathy 8
Neuropathy Therapeutics under Development by Companies 10
Neuropathy Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Neuropathy Therapeutics – Products under Development by Companies 16
Neuropathy Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Neuropathy Therapeutics Development 18
Quark Pharmaceuticals, Inc. 18
Sun Pharmaceutical Industries Limited 19
NeurogesX, Inc. 20
Pharnext SAS 21
Beech Tree Labs, Inc. 22
Neuropathy – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
capsaicin - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
QPI-1007 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
minocycline - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
mexiletine hydrochloride - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
thioctic acid [JAN] - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Drug For Neuropathy - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Immunoglobulin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SUN-44 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Drug For Toxic Neuropathies - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
N-Acetylcysteine + Lipoic Acid + Tocopherol - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Neuropathy Therapeutics – Drug Profile Updates 41
Neuropathy Therapeutics – Discontinued Products 43
Neuropathy Therapeutics - Dormant Products 44
Neuropathy – Product Development Milestones 45
Featured News & Press Releases 45
Jun 25, 2012: Baxter Announces FDA Approval For Gammagard Liquid As Treatment For Multifocal Motor Neuropathy 45
May 04, 2012: Pfizer Stops Phase III Trial Of Lyrica Capsules CV In Neuropathic Pain Associated With HIV Neuropathy 46
Apr 27, 2012: Baxter Presents Efficacy And Safety Data Evaluating Gammagard Liquid For Multifocal Motor Neuropathy At AAN Annual Meeting 46
Apr 13, 2011: Santhera To Present Catena Clinical Study Results At 2011 American Academy Of Neurology Annual Meeting 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables
Number of Products Under Development for Neuropathy, H2 2012 8
Products under Development for Neuropathy – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Quark Pharmaceuticals, Inc., H2 2012 18
Sun Pharmaceutical Industries Limited, H2 2012 19
NeurogesX, Inc., H2 2012 20
Pharnext SAS, H2 2012 21
Beech Tree Labs, Inc., H2 2012 22
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 28
Neuropathy Therapeutics – Drug Profile Updates 41
Neuropathy Therapeutics – Discontinued Products 43
Neuropathy Therapeutics – Dormant Products 44

List of Figures
Number of Products under Development for Neuropathy, H2 2012 8
Products under Development for Neuropathy – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Discovery and Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Route of Administration, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Molecule Type, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 28

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos